%0 Journal Article
%A Kobold, Sebastian
%T RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.
%J Clinical cancer research
%V 31
%N 3
%@ 1078-0432
%C Philadelphia, Pa. [u.a.]
%I AACR
%M DKFZ-2025-00280
%P 437 - 438
%D 2025
%Z Summary
%X A recent phase I clinical study tested anti-ROR1 chimeric antigen receptor (CAR) T cells in patients with chronic lymphocytic leukemia, non-small cell lung cancer, and triple-negative breast cancer. The product could be safely administered and had activity in chronic lymphocytic leukemia but less so in non-small cell lung cancer and triple-negative breast cancer. See related article by Jaeger-Ruckstuhl et al., p. 503.
%K Humans
%K Immunotherapy, Adoptive: methods
%K Receptors, Chimeric Antigen: immunology
%K Hematologic Neoplasms: therapy
%K Hematologic Neoplasms: immunology
%K T-Lymphocytes: immunology
%K Receptors, Antigen, T-Cell: immunology
%K Receptors, Antigen, T-Cell: genetics
%K Receptors, Antigen, T-Cell: metabolism
%K Leukemia, Lymphocytic, Chronic, B-Cell: immunology
%K Leukemia, Lymphocytic, Chronic, B-Cell: therapy
%K Neoplasms: immunology
%K Neoplasms: therapy
%K Carcinoma, Non-Small-Cell Lung: immunology
%K Carcinoma, Non-Small-Cell Lung: therapy
%K Carcinoma, Non-Small-Cell Lung: pathology
%K Triple Negative Breast Neoplasms: immunology
%K Triple Negative Breast Neoplasms: therapy
%K Triple Negative Breast Neoplasms: pathology
%K Female
%K Receptors, Chimeric Antigen (NLM Chemicals)
%K Receptors, Antigen, T-Cell (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39625823
%2 pmc:PMC7617067
%R 10.1158/1078-0432.CCR-24-3688
%U https://inrepo02.dkfz.de/record/298424